metformin

P=N/A, N=300, Not yet recruiting, Ohio State University | Initiation date: Sep 2024 --> Dec 2024

P2, N=14, Not yet recruiting, Amsterdam UMC, location VUmc

P3, N=124, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=273, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

P=N/A, N=40, Not yet recruiting, Sheba Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=85, Recruiting, Baylor College of Medicine

P2, N=76, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P4, N=200, Not yet recruiting, Stanford University

P1, N=64, Active, not recruiting, University of Utah | Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2024 --> Nov 2025

P=N/A, N=200, Recruiting, Nanchang Reproductive Hospital (Affiliated Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine); Nanchang Reproductive Hospita

P=N/A, N=154, Recruiting, The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University

P4, N=80, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University; Second Affiliated Hospital, School of Medicine, Zhejiang University

P2, N=130, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2026 --> Aug 2027

P1, N=87, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026

P1, N=22, Not yet recruiting, UCB BIOSCIENCES, Inc.

P=N/A, N=80, Enrolling by invitation, Shanghai 10th People's Hospital | Recruiting --> Enrolling by invitation | Phase classification: P4 --> PN/A | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=343, Completed, Astellas Pharma Inc | Phase classification: P2b --> P2

These results were also confirmed through an in vivo mouse xenograft CRC model, in which combined treatment with metformin and TRAIL induced tumor cell death, thus demonstrating the anticancer effect of their coadministration. Therefore, cotreatment of metformin and TRAIL could be an effective anticancer treatment strategy for TRAIL-resistant CRC.

P1, N=180, Recruiting, University of Alberta | Suspended --> Recruiting

This study highlights distinct differences in inflammatory markers and systemic complications between T2DM patients treated with insulin and those treated with metformin alone. Further research is needed to explore the mechanisms underlying these observations and optimize treatment strategies for T2DM patients.

Metformin may serve as a targeted therapeutic agent in HER2-positive breast cancer by modulating the miR-125a-HER2 axis and influencing on the epigenetic and EMT regulation. Further research is warranted to elucidate the therapeutic potential of metformin through these mechanisms.

P3, N=840, Recruiting, Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=32, Not yet recruiting, Gan and Lee Pharmaceuticals, USA

P=N/A, N=254, Enrolling by invitation, RenJi Hospital

P=N/A, N=138, Completed, Garvan Institute of Medical Research | Active, not recruiting --> Completed | N=264 --> 138 | Trial primary completion date: Jul 2024 --> Dec 2023

Metformin lowers the risk of tumour development through various mechanisms, including the adenosine 5'-monophosphate-activated protein kinase/liver kinase B1/mechanistic target of rapamycin (AMPK/LKB1/mTOR) pathway, insulin-like growth factor-1 receptor pathway, apoptosis, and autophagy. However, research findings are not entirely consistent. This article reviews the research progress of metformin in terms of lung cancer treatment within the past few years, aiming to provide a more comprehensive understanding of how metformin exerts its anti-cancer impact and how it can be clinically applied, as well as provide new insights for lung cancer treatment.

Our findings suggest that combining metformin with doxorubicin can enhance the anticancer activity of doxorubicin and decrease its cytotoxicity in a 4T1 breast cancer mouse model.

P1, N=32, Recruiting, Vertex Pharmaceuticals Incorporated | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024

Metformin related gastrointestinal adverse effects are associated with dose escalation, immediate release formulations, gut microbiota alteration, epigenetic predisposition, inhibition of organic cation transporters in addition to interactions with serotonin, histamine and the enterohepatic circulation. Potentially effective measures to overcome intolerance encompasses carefully objective targeted dose escalation, prescription of fixed dose combination, microbiome modulators and prebiotics, in addition to use of extended release formulations.

P2, N=30, Not yet recruiting, State University of New York at Buffalo | Trial completion date: May 2026 --> Oct 2026 | Initiation date: Aug 2024 --> Jan 2025 | Trial primary completion date: Nov 2025 --> Apr 2026

This finding may also help explain the limited clinical responses to metformin in cancers with RAS mutations. Ultimately, our study underscores the importance of understanding the impact of the genetic landscape in tailoring precision cancer preventive approaches in the context of HNSCC and other cancers that are characterized by the presence of a defined premalignant state and, therefore, amenable for cancer interception strategies.

P2, N=30, Active, not recruiting, University of Guadalajara | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Aug 2024 --> Jun 2025

P1, N=20, Not yet recruiting, Fujian Shengdi Pharmaceutical Co., Ltd.

P1, N=14, Not yet recruiting, Boehringer Ingelheim

Targeting this pathway has been approved as a therapeutic option for breast cancer and lymphoma (e.g. alpelisib, idelalisib), and there are several clinical trials underway in additional types of cancer...We report the case of a 53-year-old female with metastatic breast cancer who developed acute grade 3 hyperglycemia from a novel PI3K inhibitor, inavolisib...All patients treated with PI3K inhibitors should receive pre-treatment screening for hyperglycemia, lifestyle advice, and a glucometer to measure fasting BGL and 2-h post-dinner BGL levels twice per week for at least the first 30 days of treatment. Insulin or insulin secretagogues (e.g. sulfonylurea) may inhibit the anti-tumor activity of PI3K inhibitors, and thus treatment of PI3K inhibitor-associated hyperglycemia should prefer alternative approaches such as a low carbohydrate diet, metformin, SGLT2i, or dose reduction of the PI3K inhibitor.

The effects of metformin in reducing pain can be attributed to many factors, including its anti-inflammatory and antiaging effects. Our findings suggest that metformin may reduce pain and inflammation in patients with OA through the regulation of miR-451/CXCL16 and BCL-2.

Forty-eight 8-week-old female C57BL/6 mice were divided into four groups: group A (control group), group B (model group), group C (model+trimetazidine hydrochloride), and group D (model+metformin group), with 12 mice in each group, by using a randomized numeric table method. Compared with group B, apoptosis rate, JNK, P38 MAPK, CK-MB, BNP, TNF-α, and IL-6 expression were decreased, and LVEF, FS, PKCε, and Cav-3 expression were up-regulated in groups C and D. And group D was better than group C (P<0.05). In conclusion, metformin has a protective effect against septic cardiomyopathy, and the mechanism may be related to the inhibition of the activation of the P38 MAPK/JNK signaling pathway and the up-regulation of PKCε and Cav-3 expression.

P3, N=124, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

PINK1 exhibits low expression levels in patients with diabetic nephropathy and its expression is strongly associated with the inhibition of disease progression, thereby offering significant clinical diagnostic value. Additionally, it may serve as a potential biological marker for clinical diagnosis and treatment of diabetic nephropathy.

Importantly, metformin reversed FFA-induced iron accumulation, and this effect was attenuated by ferrostatin-1 but enhanced by erastin, RSL3, and si-GPX4. In conclusion, our findings indicate that metformin may protect against MAFLD by inhibiting iron accumulation and Lp-PLA2 expression through the ROS, ferroptosis, and apoptosis signaling pathways. This study highlights potential therapeutic strategies for managing MAFLD-related risks and emphasizes the diverse roles of metformin in maintaining hepatocyte balance.

In studies conducted on human cells and xenografts, the drug has shown its positive effects in combating these tumors by reducing proliferation, slowing the growth of cancer cells, and inhibiting metastasis. The main goal of this review is to comprehensively summarize the current state of knowledge regarding metformin in the treatment of colorectal cancer and neuroendocrine tumors.

P2, N=18, Active, not recruiting, University of Florida | Trial completion date: Jan 2025 --> Jun 2025